1. Home
  2. DECK vs ILMN Comparison

DECK vs ILMN Comparison

Compare DECK & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deckers Outdoor Corporation

DECK

Deckers Outdoor Corporation

HOLD

Current Price

$100.84

Market Cap

14.8B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$141.55

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DECK
ILMN
Founded
1973
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8B
20.5B
IPO Year
1993
2000

Fundamental Metrics

Financial Performance
Metric
DECK
ILMN
Price
$100.84
$141.55
Analyst Decision
Buy
Hold
Analyst Count
23
16
Target Price
$120.40
$121.00
AVG Volume (30 Days)
2.6M
1.7M
Earning Date
01-29-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
18.83
N/A
EPS
6.75
4.46
Revenue
$5,244,323,000.00
$4,288,000,000.00
Revenue This Year
$9.84
N/A
Revenue Next Year
$7.49
$2.38
P/E Ratio
$14.92
$31.76
Revenue Growth
12.62
N/A
52 Week Low
$78.91
$68.70
52 Week High
$223.98
$151.34

Technical Indicators

Market Signals
Indicator
DECK
ILMN
Relative Strength Index (RSI) 48.90 55.72
Support Level $99.82 $140.19
Resistance Level $103.92 $151.00
Average True Range (ATR) 3.26 4.91
MACD -0.90 -0.22
Stochastic Oscillator 11.10 55.38

Price Performance

Historical Comparison
DECK
ILMN

About DECK Deckers Outdoor Corporation

Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has nearly 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: